Abstract
Suicide is an urgent public health crisis that claimed over 48,000 lives in the US in 2022. The importance of genetics in suicide risk has been established by classical twin and family studies, and confirmed with recent large genome-wide association studies (GWAS). While the GWAS are beginning to reveal genetic risk due to common variants each with small effect on liability, these results explain only a fraction of the genetic risk. As with other complex health conditions, some of this unexplained risk is likely due to rarer variants with larger effect on liability. Using whole genome sequencing (WGS) data from 1,054 population-ascertained Utah suicide deaths, we investigated intragenic deletions as a class of genomic variation highly likely to disrupt gene function. To minimize the chance of false positive results, studied deletions were limited to those found in three large publicly-available control datasets (1000 Genomes, GnomAD, and Centers for Common Disease Genomics). Additional internal replication also required deletions to occur at least twice in WGS from an initial cohort of 670 suicide deaths then again in a second cohort of 384 suicide deaths. All results meeting these filters were manually validated. There were 11 validated deletions with at least 2-fold increase in frequency over occurrence in controls (range 2.28 to 4.46). These results implicated genes associated with risk of mental health conditions (MPST, IL4R, CDH13), epilepsy (CLCA4), intellectual disability (ZNF44), neuronal function (OSBPL2), metabolic function (FBOX36), lipid metabolism (TM9SF3), immune related functions (PIPOX, IL4R), and transcriptional repression (ZHX3). SNPs in genes implicated by the deletions have also been associated with mental health conditions, neuronal function, immune response, and other critical biological pathways including neuroinflammation and cellular response to stress. Demographic and clinical associations of suicide deaths with specific genetic deletions, highlight the prevalence of mood, anxiety and bipolar disorders and variations in age at suicide death among affected individuals. This work is the largest genome-wide analyses of WGS variation in suicide deaths to date. Pending replication, results will guide future functional studies with the eventual goals of increased understanding of mechanisms leading to risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute of Health (R01MH122412, R01MH123489, R01MH123619, R01ES032028), the American Foundation for Suicide Prevention (ED), the Brain & Behavior Research Foundation NARSAD (ED, grant number 28132, AS grant number 28686), and the Clark Tanner Foundation (HC, AS, EM, AVB). Partial support for all datasets housed within the Utah Population Data Base is provided by the Huntsman Cancer Institute (HCI), http://www.huntsmancancer.org/, and the HCI Cancer Center Support grant, P30CA42014 from the National Cancer Institute. Research was supported by NCRR grant 'Sharing statewide health data for genetic research' R01RR021746 with additional support from the Utah Department of Health and Human Services and the University of Utah.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Institutional Review Boards at the University of Utah, Intermountain Healthcare, and the Utah Department of Health and Human Services. De-identified data from suicide deaths are not classified as human subjects data for research under regulation 45CFR46.102(f). Only de-identified data was used. De-identified biospecimens and data was studied with Institutional Review Board (IRB) permissions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos